ID   KTOR2
AC   CVCL_E6D8
RX   PubMed=31900393;
CC   Population: Japanese.
CC   Doubling time: 75.6 hours (PubMed=31900393).
CC   Sequence variation: Gene fusion; HGNC; HGNC:427; ALK + HGNC; HGNC:1316; EML4; Name(s)=EML4-ALK; Note=E13A20 v1 fusion (PubMed=31900393).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C2926; Lung non-small cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_E6D9 ! KTOR2-RE
SX   Male
AG   75Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=31900393; DOI=10.1038/s41467-019-13771-5; PMCID=PMC6941996;
RA   Tsuji T., Ozasa H., Aoki W., Aburaya S., Yamamoto Funazo T., Furugaki K.,
RA   Yoshimura Y., Yamazoe M., Ajimizu H., Yasuda Y., Nomizo T., Yoshida H.,
RA   Sakamori Y., Wake H., Ueda M., Kim Y.H., Hirai T.;
RT   "YAP1 mediates survival of ALK-rearranged lung cancer cells treated
RT   with alectinib via pro-apoptotic protein regulation.";
RL   Nat. Commun. 11:74.1-74.16(2020).
//